Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim

Exclusion Criteria

• •Subject is currently receiving chemotherapy or radiation for any form of cancer.
• •Subject with conditions that are likely to prevent them from accurately and reliably completing study assessments, including evidence of moderate to severe dementia, and/or severe and progressive medical illness, as determined by the Investigator.
• •Any previous avatrombopag use.
• •Previous participation in this study; a subject may not re-enroll after prior discontinuation or completion.
• •Enrollment in another clinical study with any investigational drug or device within 30 days of Baseline (or 5 half-lives, whichever is longer); however, participation in observational studies within the previous 30 days is permitted.